AbbVie Korea
Part of AbbVie
CompanySouth Korea
AbbVie Korea develops one asset, approved (upadacitinib in Active Rheumatoid Arthritis). Mostly small molecule acting on JAK2, JAK1 and JAK3; based in South Korea.
- 1
- Asset
- Furthest stage
- Approved
- 0
- Trials
- 11
- Signals
Pipeline
1Inhibits JAK1 to suppress inflammatory cytokine signaling.
Approved, Small molecule, JAK2, JAK1, Active Rheumatoid Arthritis, ulcerative colitis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Signals20
- Similar companies6